These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


447 related items for PubMed ID: 18772860

  • 21. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension.
    Zepeda RJ, Castillo R, Rodrigo R, Prieto JC, Aramburu I, Brugere S, Galdames K, Noriega V, Miranda HF.
    Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):309-16. PubMed ID: 22703478
    [Abstract] [Full Text] [Related]

  • 22. Effects of nebivolol and atenolol on small arteries and microcirculatory endothelium-dependent dilation in hypertensive patients undergoing isometric stress.
    Arosio E, De Marchi S, Prior M, Zannoni M, Lechi A.
    J Hypertens; 2002 Sep; 20(9):1793-7. PubMed ID: 12195121
    [Abstract] [Full Text] [Related]

  • 23. Nebivolol and metoprolol: long-term effects on inflammation and oxidative stress in essential hypertension.
    Serg M, Kampus P, Kals J, Zagura M, Zilmer M, Zilmer K, Kullisaar T, Eha J.
    Scand J Clin Lab Invest; 2012 Sep; 72(5):427-32. PubMed ID: 22708640
    [Abstract] [Full Text] [Related]

  • 24. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats.
    Oelze M, Daiber A, Brandes RP, Hortmann M, Wenzel P, Hink U, Schulz E, Mollnau H, von Sandersleben A, Kleschyov AL, Mülsch A, Li H, Förstermann U, Münzel T.
    Hypertension; 2006 Oct; 48(4):677-84. PubMed ID: 16940222
    [Abstract] [Full Text] [Related]

  • 25. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension.
    Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, Tripepi G, Sesti G, Zoccali C.
    J Am Coll Cardiol; 2005 Aug 02; 46(3):518-23. PubMed ID: 16053968
    [Abstract] [Full Text] [Related]

  • 26. Protective effects of nebivolol and reversal of endothelial dysfunction in diabetes associated with hypertension.
    Georgescu A, Popov D, Dragan E, Dragomir E, Badila E.
    Eur J Pharmacol; 2007 Sep 10; 570(1-3):149-58. PubMed ID: 17612521
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release.
    Kamp O, Metra M, Bugatti S, Bettari L, Dei Cas A, Petrini N, Dei Cas L.
    Drugs; 2010 Sep 10; 70(1):41-56. PubMed ID: 20030424
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients.
    Pasini AF, Garbin U, Nava MC, Stranieri C, Pellegrini M, Boccioletti V, Luchetta ML, Fabrizzi P, Lo Cascio V, Cominacini L.
    Am J Hypertens; 2007 Apr 10; 20(4):443-50. PubMed ID: 17386354
    [Abstract] [Full Text] [Related]

  • 35. Exploring vascular benefits of endothelium-derived nitric oxide.
    Cockcroft JR.
    Am J Hypertens; 2005 Dec 10; 18(12 Pt 2):177S-183S. PubMed ID: 16373196
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Nitric oxide mediated venodilator effects of nebivolol.
    Bowman AJ, Chen CP, Ford GA.
    Br J Clin Pharmacol; 1994 Sep 10; 38(3):199-204. PubMed ID: 7826820
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 23.